149 related articles for article (PubMed ID: 20890374)
1. Opioid growth factor improves clinical benefit and survival in patients with advanced pancreatic cancer.
Smith JP; Bingaman SI; Mauger DT; Harvey HH; Demers LM; Zagon IS
Open Access J Clin Trials; 2010 Mar; 2010(2):37-48. PubMed ID: 20890374
[TBL] [Abstract][Full Text] [Related]
2. Opioid growth factor and the treatment of human pancreatic cancer: a review.
Zagon IS; McLaughlin PJ
World J Gastroenterol; 2014 Mar; 20(9):2218-23. PubMed ID: 24605021
[TBL] [Abstract][Full Text] [Related]
3. Opioid growth factor enhances tumor growth inhibition and increases the survival of paclitaxel-treated mice with squamous cell carcinoma of the head and neck.
Jaglowski JR; Zagon IS; Stack BC; Verderame MF; Leure-duPree AE; Manning JD; McLaughlin PJ
Cancer Chemother Pharmacol; 2005 Jul; 56(1):97-104. PubMed ID: 15791460
[TBL] [Abstract][Full Text] [Related]
4. Opioid growth factor (OGF) inhibits human pancreatic cancer transplanted into nude mice.
Zagon IS; Hytrek SD; Smith JP; McLaughlin PJ
Cancer Lett; 1997 Jan; 112(2):167-75. PubMed ID: 9066724
[TBL] [Abstract][Full Text] [Related]
5. Treatment of advanced pancreatic cancer with opioid growth factor: phase I.
Smith JP; Conter RL; Bingaman SI; Harvey HA; Mauger DT; Ahmad M; Demers LM; Stanley WB; McLaughlin PJ; Zagon IS
Anticancer Drugs; 2004 Mar; 15(3):203-9. PubMed ID: 15014352
[TBL] [Abstract][Full Text] [Related]
6. Opioid growth factor receptor is unaltered with the progression of human pancreatic and colon cancers.
Zagon IS; McLaughlin PJ
Int J Oncol; 2006 Aug; 29(2):489-94. PubMed ID: 16820893
[TBL] [Abstract][Full Text] [Related]
7. Design, Synthesis, and Antitumor Evaluation of an Opioid Growth Factor Bioconjugate Targeting Pancreatic Ductal Adenocarcinoma.
Budka J; Debowski D; Mai S; Narajczyk M; Hac S; Rolka K; Vrettos EI; Tzakos AG; Inkielewicz-Stepniak I
Pharmaceutics; 2024 Feb; 16(2):. PubMed ID: 38399336
[TBL] [Abstract][Full Text] [Related]
8. Growth inhibition of thyroid follicular cell-derived cancers by the opioid growth factor (OGF) - opioid growth factor receptor (OGFr) axis.
McLaughlin PJ; Zagon IS; Park SS; Conway A; Donahue RN; Goldenberg D
BMC Cancer; 2009 Oct; 9():369. PubMed ID: 19835629
[TBL] [Abstract][Full Text] [Related]
9. Human pancreatic cancer cell proliferation in tissue culture is tonically inhibited by opioid growth factor.
Zagon IS; Smith JP; McLaughlin PJ
Int J Oncol; 1999 Mar; 14(3):577-84. PubMed ID: 10024694
[TBL] [Abstract][Full Text] [Related]
10. Featured Article: Modulation of the OGF-OGFr pathway alters cytokine profiles in experimental autoimmune encephalomyelitis and multiple sclerosis.
Ludwig MD; Zagon IS; McLaughlin PJ
Exp Biol Med (Maywood); 2018 Feb; 243(4):361-369. PubMed ID: 29307283
[TBL] [Abstract][Full Text] [Related]
11. Elevated levels of opioid growth factor in the plasma of patients with pancreatic cancer.
Smith JP; Conter RL; Demers TM; McLaughlin PJ; Zagon IS
Pancreas; 2000 Aug; 21(2):158-64. PubMed ID: 10975710
[TBL] [Abstract][Full Text] [Related]
12. Mutations in the opioid growth factor receptor in human cancers alter receptor function.
Kren NP; Zagon IS; McLaughlin PJ
Int J Mol Med; 2015 Jul; 36(1):289-93. PubMed ID: 26005722
[TBL] [Abstract][Full Text] [Related]
13. Prospective oncotarget for gynecological cancer: Opioid growth factor (OGF) - opioid growth factor receptor (OGFr) axis.
Qu N; Wang X; Meng Y; Shan F
Int Immunopharmacol; 2019 Oct; 75():105723. PubMed ID: 31408839
[TBL] [Abstract][Full Text] [Related]
14. Opioid growth factor (OGF) inhibits anchorage-independent growth in human cancer cells.
Zagon IS; McLaughlin PJ
Int J Oncol; 2004 Jun; 24(6):1443-8. PubMed ID: 15138586
[TBL] [Abstract][Full Text] [Related]
15. Chronic exposure to the opioid growth factor, [Met5]-enkephalin, during pregnancy: maternal and preweaning effects.
McLaughlin PJ; Wylie JD; Bloom G; Griffith JW; Zagon IS
Pharmacol Biochem Behav; 2002; 71(1-2):171-81. PubMed ID: 11812520
[TBL] [Abstract][Full Text] [Related]
16. Opioid growth factor arrests the progression of clinical disease and spinal cord pathology in established experimental autoimmune encephalomyelitis.
Campbell AM; Zagon IS; McLaughlin PJ
Brain Res; 2012 Sep; 1472():138-48. PubMed ID: 22820301
[TBL] [Abstract][Full Text] [Related]
17. Enhanced growth inhibition of squamous cell carcinoma of the head and neck by combination therapy of paclitaxel and opioid growth factor.
McLaughlin PJ; Jaglowski JR; Verderame MF; Stack BC; Leure-Dupree AE; Zagon IS
Int J Oncol; 2005 Mar; 26(3):809-16. PubMed ID: 15703840
[TBL] [Abstract][Full Text] [Related]
18. T lymphocyte proliferation is suppressed by the opioid growth factor ([Met(5)]-enkephalin)-opioid growth factor receptor axis: implication for the treatment of autoimmune diseases.
Zagon IS; Donahue RN; Bonneau RH; McLaughlin PJ
Immunobiology; 2011 May; 216(5):579-90. PubMed ID: 20965606
[TBL] [Abstract][Full Text] [Related]
19. Opioid growth factor ([Met5]enkephalin) prevents the incidence and retards the growth of human colon cancer.
Zagon IS; Hytrek SD; Lang CM; Smith JP; McGarrity TJ; Wu Y; McLaughlin PJ
Am J Physiol; 1996 Sep; 271(3 Pt 2):R780-6. PubMed ID: 8853403
[TBL] [Abstract][Full Text] [Related]
20. Opioid growth factor regulates the cell cycle of human neoplasias.
Zagon IS; Roesener CD; Verderame MF; Ohlsson-Wilhelm BM; Levin RJ; McLaughlin PJ
Int J Oncol; 2000 Nov; 17(5):1053-61. PubMed ID: 11029512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
